Friedreich Ataxia (FA) Clinical Trials and Treatments

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansion in the FXN gene, which encodes frataxin protein. Frataxin is essential for mitochondrial function and iron homeostasis; when deficient, mitochondrial dysfunction and iron accumulation damage neurons and cardiac muscle. The disease causes progressive degeneration of the posterior columns and spinocerebellar tracts of the spinal cord, as well as the dorsal root ganglia, resulting in loss of coordination (ataxia), weakness, sensory loss, and speech impairment.

The most common symptoms of Friedreich Ataxia include Progressive loss of coordination and balance (ataxia), Weakness and spasticity in legs, Speech difficulties and difficulty swallowing, Loss of sensation in extremities, Heart abnormalities and cardiomyopathy, among others. Friedreich Ataxia affects approximately 1 in 50,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Friedreich Ataxia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. FRDA research is exploring multiple promising approaches including frataxin gene replacement therapy, antisense oligonucleotides, and compounds designed to boost remaining frataxin levels. Clinical trials are actively recruiting across all disease stages.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Friedreich Ataxia: Skyclarys (omaveloxolone). Corticosteroids and immune globulins count once each.

Friedreich Ataxia is caused by variants in the FXN gene. Nearly all cases are a homozygous GAA trinucleotide repeat expansion in FXN (66 to over 1,000 repeats); longer repeats mean earlier onset.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 50,000 people. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Friedreich Ataxia looks at the FXN gene. Nearly all cases are a homozygous GAA trinucleotide repeat expansion in FXN (66 to over 1,000 repeats); longer repeats mean earlier onset.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Friedreich Ataxia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Friedreich Ataxia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.